Nasus Pharma Ltd
NSRX· NYSE
NSRXNasus Pharma Ltd
Who holds Nasus Pharma Ltd, from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Balyasny Asset Management L.P. | 898.5K | ±0% | $3.1M | 0.1% | Aug 14, 2026 |
| Cable Car Capital, LP | 616.1K | +2.3% | $2.2M | 0.1% | Aug 14, 2026 |
| Velan Capital Investment Management LP | 359.4K | ±0% | $1.3M | 0.8% | Aug 14, 2026 |
| Hudson Bay Capital Management LP | 134.8K | ±0% | $471.7K | 0.1% | Aug 14, 2026 |
| Bleichroeder LP | 89.8K | ±0% | $314.5K | 0.1% | Aug 13, 2026 |
| Citadel Advisors LLC | 22K | New | $77K | 0% | Sep 2, 2026 |
| XTX Topco Ltd | 16.6K | New | $58.2K | 0.1% | Aug 14, 2026 |
| Renaissance Technologies LLC | 12.2K | New | $42.7K | 0.1% | Aug 13, 2026 |
| Morgan Stanley | 1K | −50.0% | $3.5K | 0% | Aug 13, 2026 |
| Caitong International Asset Management Co., Ltd | 4 | New | $14 | 0% | Aug 5, 2026 |
